Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: Study protocol for a randomized trial. by Alfvén, Tobias et al.
STUDY PROTOCOL Open Access
Neonatal resuscitation using a supraglottic
airway device for improved mortality and
morbidity outcomes in a low-income
country: study protocol for a randomized
trial
Nicolas J. Pejovic1,2,3* , Susanna Myrnerts Höök1,2,3, Josaphat Byamugisha4,5, Tobias Alfvén2,3, Clare Lubulwa4,
Francesco Cavallin6, Jolly Nankunda4,7, Hege Ersdal8,9, Giulia Segafredo10, Mats Blennow11,12,
Daniele Trevisanuto13 and Thorkild Tylleskär1,14
Abstract
Background: Intrapartum-related death is the third leading cause of under-5 mortality. Effective ventilation during
neonatal resuscitation has the potential to reduce 40% of these deaths. Face-mask ventilation performed by
midwives is globally the most common method of resuscitating neonates. It requires considerable operator skills
and continuous training because of its complexity. The i-gel® is a cuffless supraglottic airway which is easy to insert
and provides an efficient seal that prevents air leakage; it has the potential to enhance performance in neonatal
resuscitation. A pilot study in Uganda demonstrated that midwives could safely resuscitate newborns with the i-gel®
after a short training session. The aim of the present trial is to investigate whether the use of a cuffless supraglottic
airway device compared with face-mask ventilation during neonatal resuscitation can reduce mortality and
morbidity in asphyxiated neonates.
Methods: A randomized phase III open-label superiority controlled clinical trial will be conducted at Mulago
Hospital, Kampala, Uganda, in asphyxiated neonates in the delivery units. Prior to the intervention, health staff
performing resuscitation will receive training in accordance with the Helping Babies Breathe curriculum with a
special module for training on supraglottic airway insertion. A total of 1150 to 1240 babies (depending on cluster
size) that need positive pressure ventilation and that have an expected gestational age of more than 34 weeks and
an expected birth weight of more than 2000 g will be ventilated by daily unmasked randomization with a supraglottic
airway device (i-gel®) (intervention group) or with a face mask (control group). The primary outcome will be a composite
outcome of 7-day mortality and admission to neonatal intensive care unit (NICU) with neonatal encephalopathy.
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Discussion: Although indications for the beneficial effect of a supraglottic airway device in the context of neonatal
resuscitation exist, so far no large studies powered to assess mortality and morbidity have been carried out. We
hypothesize that effective ventilation will be easier to achieve with a supraglottic airway device than with a face mask,
decreasing early neonatal mortality and brain injury from neonatal encephalopathy. The findings of this trial will be
important for low and middle-resource settings where the majority of intrapartum-related events occur.
Trial registration: ClinicalTrials.gov. Identifier: NCT03133572. Registered April 28, 2017.
Keywords: Global health, Low-income country, Laryngeal mask, Supraglottic airway device, Positive pressure ventilation,
Newborn infant, Resuscitation, Neonatal mortality, Asphyxia, Asphyxia neonatorum, Intrapartum-related complications
Background
Problem statement
Since 2015, after Millennium Development Goal num-
ber 4 (MDG-4), of globally reducing by two thirds
the under-5 (years of age) mortality, was summarized,
it has become evident that neonatal mortality does
not decrease at the same pace as post-neonatal mor-
tality [1].
Of the 140 million babies born in the world annually,
7–9 million will need resuscitation at birth. The latest
estimates are that 662,000 deaths annually are caused by
intrapartum-related events, commonly referred to as
birth asphyxia, which is the third leading cause of
under-5 mortality globally [2].
Key health indicators from Uganda in 2017 show that
child (under-5) mortality decreased from 175 out of 1000
in 1990 to 53 out of 1000 in 2016 [3]. The rate of neonatal
mortality, however, is estimated at 27 out of 1000 and re-
mains unchanged despite the national roll-out of pro-
grams such as Helping Baby Breathe (HBB) [3, 4], a basic
neonatal resuscitation curriculum for resource-limited set-
tings aiming at improving skilled attendance at birth [5].
HBB implementation trials have demonstrated a reduction
in fresh stillbirths and first-day neonatal mortality. How-
ever, recent studies in India, Kenya, and Nepal assessing
long-term outcomes showed no change in overall 28-day
neonatal mortality or perinatal mortality [6, 7].
Sustainable Development Goal number 3 (SDG-3) re-
emphasizes the need of accelerating the reduction of
neonatal mortality; each country should aim for a neo-
natal mortality below 12 out of 1000 live births by 2030.
Achieving this goal will be possible only if we improve
existing neonatal resuscitation programs [8]. All birth at-
tendants, including physicians, midwives, and nurses,
should have the knowledge and skills required to per-
form effective neonatal resuscitation [9]. Innovative tools
that can strengthen existing strategies will have to be
rapidly implemented if we are to reach the 12 out of
1000 target of neonatal death by 2030.
Rationale
Providing positive pressure ventilation (PPV) is the sin-
gle most important component of successful neonatal
resuscitation [8, 9]. Yet the mortality of newborns need-
ing face mask (FM) ventilation was as high as 10% in
Tanzania [10].
Effective ventilation during neonatal resuscitation has
the potential to reduce 40% of intrapartum-related
deaths [11]. However, the delivery of proper tidal volume
is a difficult technique to master. Mask leakage, airway
blockage, and poor chest expansion have been reported
during FM ventilation [12–14].
Ventilation is routinely initiated with FM followed by
endotracheal intubation in case of FM ventilation failure
or need for prolonged ventilatory support. Endotracheal
intubation is the most difficult skill to master in neo-
natal resuscitation and performed only by experienced
physicians [15]. The use of endotracheal tube (ETT) is
not included in resuscitation guidelines aimed at low-
resource settings [16].
The American Heart Association and the European
Resuscitation Council guidelines have proposed the use
of the laryngeal mask airway (LMA) to replace FM if
ventilation is ineffective or as an alternative to ETT dur-
ing resuscitation of the late-preterm and term infants (at
least 34 weeks’ gestation or birth weight of more than
2000 g or both) if intubation is unsuccessful [17].
Several publications, including a recent Cochrane re-
view [18, 19], have shown that the LMA allowed effect-
ive PPV in most of the treated patients (range of 95–
99%) [20–24], reducing the need for intubation [25, 26].
In previous studies, an inflatable size 1 laryngeal mask
was used [21, 23–27].
The i-gel® (Intersurgical Ltd., Wokingham, Berkshire,
UK) size 1 is a new model of cuffless supraglottic airway
device that has recently been made available for new-
borns (2–5 kg). It is designed to provide an efficient seal
to the larynx without the inflatable cuff used in the trad-
itional LMA. Positioning is easy with a low risk of tissue
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compression or dislodgement [28–30]. All of these char-
acteristics make the i-gel® a potentially useful alternative
to FM and ETT, especially in settings where the staff
skills in performing PPV are insufficient [25–27]. A pro-
spective observational study of 50 children demonstrated
a success ratio of 100% for the insertion of the i-gel®. All
devices were inserted on the first attempt. The study
showed very few complications and concluded that it
seems to be a safe and efficient device for pediatric air-
way management [31].
Task shifting the use of a cuffless supraglottic airway
device to non-doctor or inexperienced health staff in
resource-limited settings could be one way to improve
outcome following newborn resuscitation. A manikin
study in Uganda demonstrated that midwives could eas-
ily insert a cuffless supraglottic airway after brief on-the-
job training: the i-gel® was also more effective than FM
in establishing PPV in the manikin. In 2015, a phase II
randomized controlled trial (RCT) on the same site
demonstrated that midwives could effectively and safely
perform resuscitation in neonates with the i-gel® [32, 33].
The effectiveness and safety of a supraglottic airway
device compared with FM, as the primary interface for
newborn resuscitation, are still identified as important
knowledge gaps. The critical outcomes of mortality and
indicators of brain damage also need to be assessed [34].
The proposed trial will follow the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guidelines [35] and provide evidence to deter-
mine whether use of a supraglottic airway device trans-
lates into better clinical outcomes and thus can be
considered part of future guidelines for neonatal resusci-
tation in resource-limited settings (Additional file 1).
The aim of the present trial will be to compare the ef-
fectiveness of two interfaces (i-gel® versus FM) for ad-
ministering PPV at birth in terms of 7-day mortality and
neonatal encephalopathy.
Methods/design
Trial design
A randomized phase III open-label superiority controlled
clinical trial will be conducted in neonates needing PPV
at birth with two parallel groups (1:1 ratio): resuscitation
with a supraglottic airway device (i-gel®) compared to
FM (standard of care).
Setting
This trial will be conducted in Uganda at the Delivery
Unit and Operating Theatre of the Department of Ob-
stetrics and Gynaecology at Mulago National Referral
Hospital, Kampala, which has about 25,000 annual
deliveries.
Inclusion criteria
Inborn infants fulfilling the following inclusion criteria
will be eligible to participate in the trial:
 Inborn baby (i.e., born in the hospital)
 Estimated gestational age of at least 34 weeks
 Estimated birth weight of at least 2000 g
 Need for PPV at birth (based on HBB algorithm)
 Parental consent.
Exclusion criteria
 Major malformations (incompatible with sustained
life or affecting the airways)
 Macerated stillbirth.
Primary outcome measures
 A composite outcome of (a) 7-day mortality or (b) ad-
mission to neonatal intensive care unit (NICU) with
neonatal encephalopathy (maximum Thompson score
of 11 or above at day 1–5 during hospitalization) or
both [36–38].
Secondary outcome measures
 Safety of i-gel® in the hands of lower cadre (non-doc-
tor) birth attendants: adverse events (AEs) and serious
adverse events (SAEs)
 Time to initiate PPV
 Heart rate at 0, 60, 90, 120, 180, 240, and 300 s
 Advanced resuscitation (chest compressions,
intubation, and drug delivery), including
intervention by supervising physician
 Early neonatal death (<7 days)
 Very early neonatal death (<24 h)
 Neonatal encephalopathy: admission to NICU with
a Thompson score of 11 or above during day 1–5
during hospitalization
 Neonatal encephalopathy: admission to NICU with
a Thompson score of 7 or above at day 1–5 during
hospitalization
 Any hospital admission during the first 7 days of life.
Procedures
Prior to interventions: training midwives
Two hundred members of the staff involved in neo-
natal resuscitation participated in a modified HBB
(2nd edition) one-day course [5] during two weeks in
November 2017. The course was held by two pedia-
tricians familiar with the use of supraglottic airway
devices and was facilitated by two or three local HBB
instructors. It consisted of a review of the HBB action
plan and practical hands-on skill stations. The HBB
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training includes simulation scenarios involving key
procedures of the action plan (thermal loss preven-
tion, stimulation, clinical assessment, airway manage-
ment, etc.) and the use of the FM (Laerdal silicon
resuscitator, Laerdal Medical, Stavanger, Norway). An
additional module for training on the use of the i-gel®
(Intersurgical Ltd.) was added. A high-fidelity model
(SimNewB Laerdal manikin, Laerdal Medical) was
used to train the staff in the use of both devices (i-
gel® and FM). SimNewB provides realistic airways and
good feedback with chest rise when effective PPV is
provided. The participants learned the insertion tech-
nique recommended by the manufacturer that is the
same in the manikin and in the neonate [26, 32]. A
silicon lubricant (not needed in newborn infants be-
cause of oral secretions) facilitated the procedure.
Three successful i-gel® insertions in the manikin were
required to partake in the study. FM ventilation was
taught in accordance with the HBB curriculum using
the NeoNatalie manikin (Laerdal Medical) and in-
cluded advanced corrective measures. In case of failed
FM ventilation, the participants were instructed to
apply the following measures before considering the alter-
native airway device: reapplication of the mask, reposi-
tioning of the head, and increase of the inspiratory
pressure. The use of suctioning was de-emphasized in ac-
cordance with the latest guidelines.
Recruitment and implementation
Investigators and trained research assistants will partici-
pate in the enrollment of participants in accordance with
the inclusion criteria (Fig. 1). Neonates will be recruited
every day around the clock consecutively until sample
size is reached. Data from babies will be used in the trial
only after written parental consent is given. A senior in-
vestigator will be available at all times to discuss con-
cerns raised by parents or clinicians during the course of
the trial.
Tagging of newborns
All neonates enrolled in the trial and their mothers will
be tagged with a trial bracelet with a unique trial ID
number to facilitate matching and retrieval.
Fig. 1 Trial profile (CONSORT flowchart)
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Randomization
Cluster randomization will be used, choosing day-by-day
clusters. For practical reasons, individual randomization
is not feasible, so all neonates enrolled in the same day
(representing a cluster) will be randomly assigned to the
same treatment. This approach randomly assigns daily
groups of neonates rather than individual neonates, and
neonates within any one day are likely to respond in a
similar manner; hence, their data cannot be assumed to
be independent. The clustering structure of the data was
taken into account in sample size calculation and data
analysis planning. A randomization list will be made by
an independent statistician using block randomization
with block sizes of 4–8. The allocation remains con-
cealed until the actual trial day when the randomization
envelope is opened by the surveillance officer on duty at
8 a.m. The midwives are informed at the beginning of
each shift of the assigned treatment. The envelopes and
assignment cards are discarded after use. The assigned
procedure will then be performed until the next
randomization. To provide proper PPV to the baby, the
American Heart Association and European Resuscitation
Council guidelines recommend switching to a supraglot-
tic airway device if the resuscitator considers that the
FM is failing [17]. We recommend the resuscitator to
optimize the ventilation during 3 mins before consider-
ing switching ventilation option from FM to i-gel and
vice versa, to keep contamination between arms low.
The intervention
Oral consent will be sought for all mothers admitted to
the delivery unit, followed by deferred written informed
consent as soon as practicable for mothers of babies eli-
gible for the trial. HBB principles of the golden minute
will be applied to all babies not crying at birth, including
drying, stimulation, and assessment. A stopwatch will be
started at the time of birth by a research assistant for all
eligible participants. In the case of “baby is not breath-
ing” after initial steps, the midwife will immediately
(after cutting the cord) move the babies in need of PPV
to the resuscitation area. Inflations will be administered
with room air at a rate of 40 to 60/min with a 240-mL
silicon self-inflating bag and a pop-off valve limit at 35
cm H2O (Laerdal Medical). Silicone, round-shaped FM
(size 1, Laerdal Medical) or i-gel® (size 1) will be available
at each delivery. The duration of resuscitation will be de-
fined as the time period from start of ventilation to the
establishment of spontaneous breathing. Heart rate will
be registered with a dry-electrode electrocardiogram
monitor (NeoBeat Newborn Heart Meter, Laerdal Global
Health, Stavanger Norway) featuring fast signal acquisi-
tion [39]. All babies with a 5-min APGAR (Appearance,
Pulse, Grimace, Activity and Respiration) score of less
than 7, respiratory distress, hypothermia (axillary
temperature of less than 36.0 °C), or signs of encephal-
opathy will be transferred to the NICU. Resuscitation
data, any contamination between arms, follow-up con-
tact, and admission to the neonatal unit will be recorded
by a research assistant. All interventions will be recorded
on video to ensure quality assurance and data collection.
Management from supervising physician
Advanced resuscitation can be initiated in accordance
with local hospital and International Liaison Committee
on Resuscitation (ILCOR) guidelines [34], should a
supervising physician be available. This can include use
of alternative airways, including ETT, chest compres-
sions, and drug administration.
Contamination between arms
Contamination between arms (switching to the alterna-
tive device) will be possible after 3 min of sustained PPV,
should ventilation be deemed unsatisfactory. The alter-
native device will be accessible in an easily accessible
box on the resuscitation table. This possible scenario will
be practiced during the training. In all cases, a report
specifying the reasons for switching to the alternative
airway device will be filled out.
Masking
Health-care providers (midwives) performing resuscita-
tion and the research assistant recording resuscitation
data in the delivery ward cannot be masked to the allo-
cation arm. However, the examiners assessing neonatal
encephalopathy outcomes will be masked to the arm al-
location. Outcome examiners will be exclusively working
at the NICU, physically separated from where the resus-
citations are performed. The arm allocation will not
appear on the medical chart. Thus, arm allocation of ad-
mitted patients will not be identifiable by the outcome
examiner. The independent data monitoring committee
(IDMC) will have access to arm allocation when per-
forming interim analysis and assessment of AEs/SAEs.
The statistician who will perform data analysis will be
masked to treatment allocation.
Sample size
Considering our previous phase II trial, we estimate that
a reduction of 25% of adverse outcomes may be possible.
A sample size of 954 participants (477 per arm) is
required to have a 90% chance of detecting, as signifi-
cant at the 5% level, a decrease in the primary outcome
measure from 40% in the standard-of-care arm to 30%
in the supraglottic-airway arm. The sample size is
increased to 1150 or 1240 because of the day-by-day
cluster randomization, assuming an intra-class correl-
ation of 0.10 and an average daily enrollment of three or
four participants, respectively.
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Data collection and monitoring
Assessment and collection of outcomes
The primary outcome will be assessed in two parts. Mor-
tality outcome will be collected daily at the NICU for
admitted trial patients until day 7. Non-hospitalized par-
ticipants will receive a scheduled appointment or phone
call by a trial nurse with the mother at day 7 assessing the
health of the baby. For all hospitalized participants, mor-
bidity by neonatal encephalopathy will be assessed by a
trial doctor masked to the arm allocation. This assessment
will take place daytime on day 1, 2, 3, 4, and 5 or until dis-
charge, using Thompson score (Table 1).
Data from the pre-coded case report form (CRF) will
be entered into Open Data Kit (ODK) (https://opendata-
kit.org), an open-source suite of tools that helps
researchers manage mobile data collection solutions.
The data will be stored on an encrypted server and sub-
sequently transferred to a statistical software package for
analysis.
The CRFs will be pre-tested before the commence-
ment of the trial. Data from the birth attendants’ ques-
tionnaire and the CRFs will be filled in by the birth
attendants and will be continuously entered into ODK.
Videos will be recorded as a quality control. The neo-
natal resuscitation algorithm will be put in place to en-
sure that all interventions are standardized. A proper
light source is needed on the table. Headlamps will act
as backup in case of a power shortage at night.
Independent data monitoring committee
An IDMC consisting of four members—a statistician, an
obstetrician, and two pediatricians—was appointed. They
are operating in accordance with the IDMC charter
which is developed with the members.
The timing of the interim analysis will be carried out
by the IDMC. It will be planned when about half of the
events have occurred, following the DAMOCLES (Data
Monitoring Committees: Lessons, Ethics, Statistics)
group recommendations [40].
The IDMC will ensure that the trial protocol was
followed and control the adequacy of enrollment and
randomization. The interim data will also assess quality
standards and adherence to ethical requirements.
The interim analysis will be performed by the IDMC
statistician unmasked to the treatment allocation. Based
on this, the IDMC will make recommendations on the
continuation of the trial and its modifications or decide
on potential termination in case of harm.
Statistical analysis
A detailed statistical analysis plan—based on the princi-
ples in this section—will be developed before the statistical
analysis of the trial. Data analysis will be performed by
using the statistical software packages Stata, SAS, and R.
All tests will be two-sided, and a P value of less than 0.05
will be considered statistically significant. Missing data will
be considered, and appropriate imputations will be dis-
cussed and performed when appropriate. Statistical ana-
lysis will include an unadjusted analysis followed by an
adjusted analysis. The primary outcome will be compared
between the two treatment arms by using the chi-squared
test. The secondary outcomes will be compared by using
the chi-squared test or Fisher’s test (categorical outcomes)
and using the Student’s t test or Mann–Whitney test (con-
tinuous outcomes). Mixed-effect regression models will be
estimated to evaluate the effect of the treatment on binary
outcomes, adjusting for clusters (random effect) and clin-
ically relevant confounders. Data analyses will be per-
formed on an intention-to-treat (ITT) basis. However,
Table 1 Timeline of the trial
Enrollment Allocation Admission neonatal intensive care unit Follow-up
Time point T-1 Day 0 Day 1 Day 2–5 Day 7
Enrollment
Eligibility screen ×
Prior oral consent ×
Deferred consent ×
Randomization ×
Interventions
Resuscitation ×
Assessments
Active monitoring of resuscitation ×
Video recording ×
Neurological status × ×
Mortality assessment × × ×
Pejovic et al. Trials          (2019) 20:444 Page 6 of 9
since the trial is prone to some contamination (i.e., the
person resuscitating may decide to shift to the other
device) which can be limited by appropriate training but
not entirely prevented, a per-protocol analysis and a
contamination-adjusted ITT analysis will also be per-
formed. These results will be considered along with the
primary ITT analysis when drawing the conclusions of the
trial. Subgroup analyses—per treatment center, time of the
day (i.e., day/night), and per birth mode—will be carried
out with exploratory purpose.
Safety
Resuscitations will be continuously monitored by video
and observed by the attending midwife or physician and
the researcher assistant in order to detect AEs and SAEs.
Safety measures will include monitoring of SAEs and de-
tection of unexpected changes in incidence of common
neonatal complications. The AEs will be managed by the
attending hospital physician/midwife/researcher and
followed until resolution or until a stable clinical end-
point is reached by the clinician responsible for the care
of the recruited patient.
If there is a reasonable suspected causal relationship
with the intervention, SAEs will be reported to the Mulago
Research and Ethics Committee (MREC) to guarantee the
safety of the participants. Any suspected unexpected ser-
ious adverse reactions (SUSARs) with or without a reason-
ably plausible causal relationship with use of the
supraglottic airway will also be reported to the MREC.
Ethical considerations
The protocol was approved by the institutional review
board of Mulago National Referral Hospital, Uganda; the
Uganda National Council of Science and Technology;
the Director General from the Ministry of Health,
Uganda (MREC 1168); and the Regional Committee for
Medical and Health Research Ethics (REK South East
reference number 2017/989) in Norway.
Extensive discussions with clinical experts and members
of the ethical board were necessary to solve the problem
of obtaining consent without delaying the intervention. A
two-tier procedure for consent will be implement in this
trial because it involves unexpected care of critically ill
newborns. All mothers entering the labor ward irrespect-
ive of whether their baby is suspected of filling inclusion
criteria will receive brief information of the trial after
which oral consent will be sought. Mothers whose infants
are found eligible at birth will be approached for full writ-
ten deferred consent for continuing participation. All in-
formation, including informed consent and the material
used in the trial, will be translated in English and Luganda
in a clearly understandable form. A senior investigator will
be available to discuss any additional questions regarding
the trial.
Sustainability and scalability
A simplified neonatal resuscitation program that can re-
duce neonatal deaths due to perinatal asphyxia is the
highest newborn global health research priority beyond
2015 [41]. This trial will try to demonstrate the first
phase of scalability of an innovative approach to new-
born resuscitation.
The training module for supraglottic airway use can eas-
ily be integrated to current neonatal resuscitation pro-
grams [33]. The cost-effectiveness of a supraglottic airway
in a low-resource setting needs to be assessed. Such an in-
vestment can be justified only if there is a substantial dif-
ference between the supraglottic airway and FM. We
estimate that a 25% reduction in adverse outcomes is a
clinically significant difference large enough to have policy
implications. A reusable cuffless device is already available
but is still cost-prohibitive [29], so it will be crucial to ex-
plore how the unit cost can be reduced. A historical paral-
lel could be the substantial drop in the cost of anti-
retroviral therapy against HIV over the last decades [42],
allowing scale-up of treatment to a level that previously
seemed impossible in low-resource settings.
Discussion
Newborn resuscitation training and simulation-based cur-
riculum show mixed results in relation to their impact on
newborn mortality [3, 4] and their effect on neurological
morbidity remains unknown [43]. Further improvement
of neonatal resuscitation performance is crucial.
This large trial is the first to assess the impact on mor-
tality/morbidity of the use of a supraglottic airway device
during neonatal resuscitation. It is powered to 90% and
designed to add evidence lacking in this field. To the best
of our knowledge, only four RCTs comparing LMA or
supraglottic airway to FM ventilation including 636 pa-
tients have previously been published [18, 19, 25, 26, 32].
They have focused mainly on vital sign outcomes or suc-
cessful resuscitation [34]. Safety and long-term outcomes
remain important knowledge gaps. This task-shifting
intervention involves midwives as they are the frontline
health workers in many settings where newborn mortality
is high. The burden of disease from intrapartum-related
events can be reduced if simple and robust technologies
for newborn resuscitation can be identified [44].
The trial will also monitor neonatal outcome data until
day 7. We hypothesize that effective ventilation will be
easier to perform with the supraglottic airway device and
significantly decrease early neonatal mortality and brain
damage from neonatal encephalopathy. Results from this
large trial will contribute to provide evidence that can help
define best practice advice for future guidelines.
Trial status
The trial started recruiting participants on May 8, 2018.
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